Uncovering How Horses Metabolize the Growth Hormone Secretagogue Ibutamoren

Ibutamoren (MK-677) is a potent, non-peptidic growth hormone secretagogue (GHS) that stimulates the release of growth hormone (GH). While often investigated for conditions like GH deficiency and muscle wasting, its use in sports raises concerns due to its performance-enhancing potential, particularly in equestrian disciplines. Understanding how the body breaks down (metabolizes) ibutamoren is crucial for developing effective detection methods and ensuring drug safety. This study specifically aimed to characterize the metabolic pathways of ibutamoren in equine liver microsomes, a key step for anti-doping efforts and veterinary pharmacology.

The study successfully identified 7 distinct metabolites of ibutamoren in equine liver microsomes, indicating complex metabolic processing. The primary metabolic pathway observed was hydroxylation, accounting for approximately 68% of the total metabolic activity, followed by N-dealkylation and subsequent oxidation. The most abundant metabolite, M1, was identified as a hydroxylated derivative at the phenyl ring, representing 45% of the total metabolites detected after 30 minutes of incubation. Two other significant metabolites, M2 and M3, were also hydroxylated products, contributing 18% and 12% respectively. Glucuronidation, a common detoxification pathway, was observed as a minor pathway, forming 2 minor metabolites, each less than 5% of the total. These findings suggest that equine metabolism of ibutamoren involves multiple oxidative steps.